HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Duane Reade Sale Reflects “Industry Issues”: Rx-To-OTC “Shifts” Cited

This article was originally published in The Tan Sheet

Executive Summary

Market shift from Rx-to-OTC products is among pharmacy industry issues cited by the retail drug chain Duane Reade in explaining its decision to sell to the private equity firm Oak Hill Capital Partners

You may also be interested in...

OTC Sales Healthy During Severe Flu Season, P&G, Drug Chains Announce

Stronger than expected sales for OTC cold and flu remedies through the fall and early winter prompted Procter & Gamble to raise its fiscal second quarter sales and earnings forecast Jan. 7

Eckerd Drug Put On Sale By J.C. Penney; Potential Milestone In Retail Market

The potential sale of the Eckerd drug store chain could set the stage for the first major expansion by a Canadian firm into the U.S. pharmacy business

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts